Denmark-based 7TM Pharma has raised €16.5 million in a new round of financing. The round was led by SR One Limited, GlaxoSmithKline's independent corporate healthcare venture fund. 7TM says the money will be used to support the company's drug discovery and drug development programs, particularly of the drug candidates Obinepitide (TM30338) and TM30339, both for the treatment of obesity.
- read this release for more on the round